.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Exciting Advances in the Treatment of Advanced NSCLC

EP. 1: PD-1 Inhibitors in NSCLC: Combination or Monotherapy

November 20th 2018

EP. 2: First-Line Treatment Recommendations Based on TMB

November 20th 2018

EP. 3: The Role of Immunotherapy in Squamous NSCLC

November 20th 2018

EP. 4: IMpower-150: EGFR-Mutated Subset Analysis

November 20th 2018

EP. 5: Blood-Based TMB as a Predictive Biomarker in NSCLC

November 20th 2018

EP. 6: Second-Line after I-O: Where Do We Go from There?

November 20th 2018

EP. 7: PACIFIC Trial: Positive New Data in OS & PFS

November 20th 2018

EP. 8: Superiority of Third-Generation EGFR TKI

November 20th 2018